As the underlying genetic drivers involved in RCC development were determined with their impacts on biological pathways, therapies targeting the vascular endothelial cell growth factor (VEGF) and mTOR signalling pathways were developed [7,28,29]. Here, MTOR is linked to renal cell carcinoma.